Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18796386 | 0.98 | KMT2A (0.43) | KMT2AMAPTHTR2BMAPK1DAO | |
| SCHEMBL18816251 | 0.87 | KMT2A (0.40) | KMT2AMAPTMAPK1 | |
| SCHEMBL18796472 | 0.83 | KMT2A (0.35) | KMT2AMAPTTACR1ALDH1A1 | |
| SCHEMBL18816187 | 0.74 | IDH1 (0.40) | KMT2A | |
| SCHEMBL18816189 | 0.72 | HSD11B1 (0.31) | KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL18796470 | 0.71 | TACR1 (0.31) | TACR1 | |
| SCHEMBL12296177 | 0.70 | PNMT (0.37) | KMT2AMAPTDAOALOX5ALDH1A1 | |
| SCHEMBL10326159 | 0.70 | TACR1 (0.39) | KMT2ATACR1ALDH1A1HPGDMCOLN3 | |
| SCHEMBL10327102 | 0.70 | TACR1 (0.39) | KMT2ATACR1ALDH1A1HPGDMCOLN3 | |
| SCHEMBL10326158 | 0.70 | TACR1 (0.39) | KMT2ATACR1ALDH1A1HPGDMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988390-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988390-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988390-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-09-21 | — | — | US | disclosed |
| WO-2017072341-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017072341-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267680-A1 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | XDH, HPRT1, IMPDH1 | KMT2A 4753/4885MAPT 14/4885HTR2B 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.